Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Puma Plummets On Another Neratinib NDA Delay

This article was originally published in Scrip

Executive Summary

Puma Biotechnology Inc. fell 21.1% to close at $27.92 per share on March 29 after it revealed a second major delay for the company's new drug application (NDA) submission to the US FDA for neratinib as an extended adjuvant treatment for early-stage HER2-positive breast cancer.

Advertisement

Related Content

Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol

Topics

Advertisement
UsernamePublicRestriction

Register